How to Get Testosterone Cypionate in West Virginia

Who Can Prescribe Testosterone Cypionate in West Virginia

Any provider holding an active West Virginia prescriptive authority license and a DEA Schedule III registration can prescribe testosterone cypionate. That includes MDs, DOs, nurse practitioners, and physician assistants.

West Virginia Board of Medicine regulations require that NPs practicing independently (a right established under WV Code §30-7-15a) maintain a collaborative agreement for the first three years of practice, after which full prescriptive authority applies. PAs prescribe under physician supervision per WV Code §30-3E. For testosterone specifically, the prescribing provider must document a clinical diagnosis of hypogonadism before writing the prescription.

The Endocrine Society 2018 Clinical Practice Guideline recommends testosterone therapy only in men with "unequivocally low serum testosterone levels and clinical signs and symptoms of androgen deficiency." That means the prescriber should confirm symptoms (fatigue, reduced libido, loss of lean mass) alongside lab values. A single low reading is insufficient. Two separate morning draws showing total testosterone below 300 ng/dL are the accepted standard [1].

Urology and endocrinology specialists are common prescribers, but primary care physicians write the majority of testosterone prescriptions in the United States. A 2020 analysis in the Journal of the Endocrine Society found that primary care providers initiated 60.8% of new testosterone prescriptions nationwide [2]. West Virginia follows this pattern. Rural counties with limited specialist access rely heavily on family medicine providers for TRT management.

Telehealth Prescribing Rules in West Virginia

West Virginia allows testosterone cypionate to be prescribed via telehealth. This is a significant access point for patients in the state's rural southern and eastern counties.

Following the COVID-era expansion of telehealth, West Virginia codified permanent telehealth parity through WV Code §33-57, which requires insurers to cover telehealth visits at the same rate as in-person encounters. The DEA's updated telemedicine prescribing rule (effective 2025) still requires at least one synchronous audio-video evaluation before a provider prescribes a Schedule III controlled substance like testosterone cypionate [3]. An audio-only phone call does not satisfy this requirement for initial prescriptions.

Practically, a first telehealth visit for TRT in West Virginia looks like this: the patient completes labs at a local draw site (LabCorp and Quest both operate collection centers in Charleston, Morgantown, Huntington, and Parkersburg), uploads results to the telehealth platform, then meets the provider by video. If the labs confirm hypogonadism, the provider can e-prescribe testosterone cypionate directly to the patient's pharmacy.

Turnaround time varies by platform. Most patients receive their prescription within 3 to 7 business days of their initial video consultation, assuming labs are already completed. Patients who need to schedule labs first should add 5 to 10 business days for draw, processing, and provider review.

Required Labs Before Starting Testosterone Cypionate

The lab workup is not optional. Both the American Urological Association (AUA) and the Endocrine Society require biochemical confirmation of testosterone deficiency before treatment begins [1][4].

The baseline panel includes:

• Total testosterone (two separate morning draws, collected between 7:00 and 10:00 AM when diurnal levels peak)
• Free or bioavailable testosterone (calculated or measured, especially when SHBG is suspected to be abnormal)
• Complete blood count (CBC) with hematocrit (testosterone raises erythropoiesis; baseline hematocrit above 50% is a relative contraindication)
• PSA (prostate-specific antigen, to rule out occult prostate pathology)
• Lipid panel
• Comprehensive metabolic panel (liver and kidney function)
• LH and FSH (to distinguish primary from secondary hypogonadism)

The AUA's 2018 guideline states: "Clinicians should measure a total testosterone level as the initial diagnostic test and should confirm the diagnosis by repeating a total testosterone level on a separate day" [4]. Skipping the confirmatory draw exposes the provider to liability and the patient to unnecessary treatment. Morning cortisol, prolactin, and thyroid function may also be ordered if the clinical picture suggests pituitary pathology.

Once therapy begins, follow-up labs are drawn at 3 months, 6 months, and then every 6 to 12 months. The key monitoring targets: trough testosterone between 400 and 700 ng/dL, hematocrit below 54%, and stable PSA.

Standard Dosing and Administration

Testosterone cypionate is dispensed as an oil-based injectable solution, typically at 200 mg/mL in 1 mL or 10 mL vials. The FDA-approved prescribing information specifies a dose range of 50 to 400 mg intramuscularly every 2 to 4 weeks for androgen replacement.

In clinical practice, most providers prescribe 100 to 200 mg every 7 to 14 days. Weekly injections produce more stable serum levels and fewer troughs compared to biweekly protocols. A pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that 100 mg weekly produced steadier testosterone concentrations (coefficient of variation 18%) than 200 mg every two weeks (coefficient of variation 42%) [5].

Subcutaneous injection has gained acceptance as an alternative to intramuscular delivery. A 2017 study by Al-Futaisi et al. in Translational Andrology and Urology showed that subcutaneous testosterone cypionate at equivalent doses achieved comparable serum levels with less injection-site pain and easier self-administration [6]. Many telehealth TRT providers now default to subcutaneous protocols using 25- to 27-gauge, half-inch needles injected into abdominal or deltoid subcutaneous tissue.

Dose titration follows lab results. If trough levels remain below 400 ng/dL after 6 to 8 weeks on 100 mg weekly, the dose is increased by 20 to 40 mg increments. If hematocrit rises above 54%, the dose is reduced or the injection frequency is increased to lower peak levels.

Filling the Prescription: Retail and 503A Pharmacies in West Virginia

Testosterone cypionate is classified as a Schedule III controlled substance under both federal and West Virginia law (WV Code §60A-2-210). Prescriptions can be filled at any WV-licensed retail pharmacy (CVS, Walgreens, Rite Aid, Fruth Pharmacy, independent pharmacies) that stocks Schedule III medications.

Generic testosterone cypionate is widely available. A 10 mL vial of 200 mg/mL generic testosterone cypionate typically costs $30 to $75 without insurance at West Virginia retail pharmacies, based on GoodRx pricing data. Brand-name Depo-Testosterone runs significantly higher ($150 to $300+ per vial) and offers no pharmacologic advantage.

West Virginia also permits 503A compounding pharmacies to prepare patient-specific testosterone cypionate formulations. This route is relevant for patients who need:

• Non-standard concentrations (e.g., 100 mg/mL for lower-volume injections)
• Alternative carrier oils (grapeseed or sesame oil for patients with cottonseed allergy)
• Combination formulations prescribed by their provider

Under 21 USC §353a, 503A pharmacies must compound in response to a valid patient-specific prescription. They cannot batch-produce testosterone for general distribution. West Virginia's Board of Pharmacy oversees in-state 503A facilities, and out-of-state 503A pharmacies may ship into West Virginia if they hold a nonresident pharmacy license.

The T-Trials, a coordinated set of seven placebo-controlled trials published in the New England Journal of Medicine (N=790, men aged 65 and older with testosterone <275 ng/dL), confirmed that testosterone gel treatment for one year improved sexual function, physical activity, and mood compared with placebo [7]. While those trials used a gel formulation, the pharmacologic principle applies to cypionate: adequate replacement levels produce measurable clinical benefit.

Insurance Coverage and Prior Authorization in West Virginia

Coverage for testosterone cypionate varies sharply by payer. Generic injectable testosterone cypionate sits on most commercial formularies, but prior authorization is common.

West Virginia Medicaid does not cover testosterone cypionate for male hypogonadism. This creates a meaningful access barrier for the roughly 29% of West Virginians enrolled in Medicaid. Patients on Medicaid who need testosterone therapy will typically pay out of pocket or use manufacturer discount programs and pharmacy discount cards.

Commercial insurers (Highmark Blue Cross Blue Shield WV, The Health Plan, Aetna, United Healthcare) generally cover generic testosterone cypionate with prior authorization. The prior authorization packet typically requires:

• Two documented morning total testosterone levels below 300 ng/dL
• ICD-10 code E29.1 (testicular hypofunction)
• Documentation of signs and symptoms
• Baseline PSA and hematocrit
• Provider attestation that the patient does not have contraindications (breast or prostate cancer, untreated polycythemia, untreated severe sleep apnea)

Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School and author of Testosterone for Life, has noted: "The greatest barrier to appropriate testosterone therapy is not medical, it is administrative. Insurance requirements often delay treatment by weeks, sometimes months, for a diagnosis that is straightforward to confirm" [8].

For Medicare Part D plans in West Virginia, testosterone cypionate is on most formularies at Tier 2 or Tier 3. Copays range from $10 to $45 per fill depending on the plan. The coverage determination process mirrors commercial PA requirements.

Transferring a Testosterone Cypionate Prescription to West Virginia

Patients relocating to West Virginia or visiting for extended periods can transfer an existing testosterone cypionate prescription from another state. West Virginia accepts controlled substance prescription transfers under WV Board of Pharmacy Rule §15-1-14.

The process works as follows. The patient contacts their new WV pharmacy and provides the originating pharmacy's name and phone number. The receiving pharmacist calls the transferring pharmacy, verifies the prescription details (drug, dose, quantity, refills remaining, prescriber DEA number), and processes the transfer. For Schedule III substances, the DEA permits one transfer per prescription fill. If refills remain, the entire prescription transfers.

There is a catch. If the original prescription was written by an out-of-state telehealth provider who is not licensed in West Virginia, the patient will need to establish care with a WV-licensed provider to continue receiving refills once the transferred prescription runs out. West Virginia requires that telehealth prescribers of controlled substances hold an active WV medical license.

Patients moving from states with testosterone clinics or optimization centers should plan ahead. Request a copy of all lab work (baseline and follow-up) and a treatment summary from the current provider. This documentation allows the new WV provider to continue the established protocol without unnecessary repeat testing or dose resets.

Safety Monitoring and Long-Term Considerations

Testosterone replacement is not a short-term therapy. Most men who begin TRT continue indefinitely. That makes safety monitoring mandatory.

The primary acute risk is erythrocytosis. Testosterone stimulates erythropoietin production, raising red blood cell mass. The Endocrine Society guideline recommends checking hematocrit at 3 to 6 months after initiation and annually thereafter. If hematocrit exceeds 54%, the dose should be reduced, the injection interval lengthened, or therapeutic phlebotomy performed [1].

Cardiovascular safety was a subject of debate for years. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, provided the most definitive answer to date. In men aged 45 to 80 with hypogonadism and preexisting or high risk for cardiovascular disease, transdermal testosterone did not increase the incidence of major adverse cardiac events compared with placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17) over a mean follow-up of 33 months [9]. Dr. Shalender Bhasin, principal investigator of TRAVERSE and Professor of Medicine at Harvard Medical School, stated: "These findings should provide reassurance to clinicians and patients that testosterone replacement therapy, when appropriately indicated, does not increase the risk of major cardiovascular events" [9].

Prostate monitoring remains important. While testosterone therapy does not cause prostate cancer (a conclusion supported by multiple meta-analyses), it is contraindicated in men with known prostate cancer. PSA should be checked at baseline, 3 to 6 months, and annually. A PSA increase of more than 1.4 ng/mL within 12 months of starting therapy warrants urologic referral [1].

Other monitoring points include bone mineral density (testosterone improves BMD in hypogonadal men), mood and libido assessment, and periodic evaluation of fertility status. Testosterone suppresses spermatogenesis through hypothalamic-pituitary-gonadal axis suppression. Men who wish to preserve fertility should discuss alternatives (clomiphene citrate, hCG co-administration) with their prescriber before starting testosterone cypionate [10].